A review of adjuvant therapy options for kidney cancer
In this paper, published in Current Treatment Options in Oncology [...]
Lymph node dissection identifies patients at high risk of kidney cancer spread
A recent study published in the journal Science Direct suggests that [...]
ESOU 2019: Adjuvant therapy after nephrectomy for high-risk renal cell carcinoma
The following presentations were given at the European Association of [...]
MD Anderson Cancer Center 13th Update on the Management of Genitourinary Malignancies Conference
The MD Anderson Cancer Center (MDACC) 13th Update on the [...]
ESMO 2018: Interviews with the kidney cancer experts
The following video interviews with kidney cancer experts from the [...]
ESMO 2018: Adjuvant axitinib versus placebo in patients at high risk of RCC recurrance
Results from the latest adjuvant study with a vascular endothelial [...]
Adjuvant therapy for renal cell carcinoma
The following articles from various urology conferences in 2018 summarise [...]
Adjuvant sunitinib may increase symptoms and reduce quality of life in kidney cancer
A recent article in Annals of Oncology reports new patient-reported outcomes [...]
Adjuvant therapy with TKIs has no benefit for high-risk kidney cancer
According to the results of a recent meta-analysis of three [...]
Axitinib fails as an adjuvant therapy for high risk kidney cancer
The phase 3 ATLAS clinical trial to assess axitinib as [...]
